01—Abstract
Summary
Summary of the 8-K filed June 27, 2025. Cited figures are marked; the original filing is the authoritative source.
At its June 26, 2025 Annual Meeting of Shareholders, United Therapeutics Corporation's shareholders approved an amendment and restatement (the 2025 Restatement) of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the Plan).
The Board had previously approved the 2025 Restatement on the recommendation of its Compensation Committee, and it is effective June 26, 2025. The Restatement increases the maximum number of shares of common stock issuable under the Plan by 950,000 shares, extends the Plan's expiration date to April 24, 2035, and raises the Lead Independent Director retainer under the non-employee director compensation program by $5,000a per year. Shareholders also elected all twelve director nominees to one-year terms, approved an advisory resolution on executive compensation, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2025.
The Plan amendment received 36,901,484 votes for and 3,277,695 votes against, with 27,534 abstentions and 1,296,357 broker non-votes. The advisory say-on-pay vote received 38,413,776 votes for and 1,763,712 against. Each director nominee received more votes for than against, though vote margins varied; for example, Christopher Causey received 34,893,687 votes for and 5,296,661 against.
The filing is largely administrative. Its investor-relevant content is the expanded equity award capacity under the Plan, the extended plan term, and the shareholder vote results. Full details of the Plan are in Exhibit 10.1, and additional information is in the Company's April 29, 2025 proxy statement.
02—Key points
Key Highlights
- Shareholders approved the 2025 Restatement of the Amended and Restated 2015 Stock Incentive Plan at the June 26, 2025 Annual Meeting; it is effective June 26, 2025.
- The Plan's maximum issuable share count increases by 950,000 shares.
- The Plan's expiration date is extended to April 24, 2035.
- The Lead Independent Director retainer increases by $5,000 per year under the non-employee director compensation program.
- Plan amendment vote: 36,901,484 for, 3,277,695 against, 27,534 abstentions, and 1,296,357 broker non-votes.
- Advisory say-on-pay vote: 38,413,776 for and 1,763,712 against, with 29,225 abstentions.
- Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for 2025, with 39,345,917 votes for and 2,142,852 against.
03—Questions
Frequently Asked Questions
What changed in the Stock Incentive Plan?
The 2025 Restatement increases the maximum number of shares that may be issued under the Plan by 950,000, extends the Plan's expiration date to April 24, 2035, and increases the Lead Independent Director retainer by $5,000 per year.
Who approved the Plan amendment and when?
The Board approved the 2025 Restatement on the recommendation of its Compensation Committee, and the Company's shareholders approved it at the June 26, 2025 Annual Meeting. The effective date is June 26, 2025.
How did shareholders vote on the directors?
All twelve nominees were elected to one-year terms. Each received more votes for than against; for example, Louis Sullivan received 36,302,169 votes for and 3,875,030 against, and Judy Olian received 39,832,045 votes for and 357,023 against.
Where can investors find more detail on the Plan?
The full Plan text is attached as Exhibit 10.1 to the 8-K. Further detail is under Proposal No. 3 in the Company's Definitive Proxy Statement on Schedule 14A filed April 29, 2025.
04—Continue